Add-on-Statin Extended Release Nicotinic Acid/Laropiprant but Not the Switch to High-Dose Rosuvastatin Lowers Blood Pressure: An Open-Label Randomized Study
Table 2
Clinical and laboratory parameters at baseline and 3 months after treatment*.
Baseline
3 months
Percentage change (%)
Body weight (kg)
Switch-to-rosuvastatin 40 mg
79 ± 10
79 ± 9
0
Add-on-statin ER-NA/laropiprant
81 ± 10
81 ± 10
0
SBP (mmHg)
Switch-to-rosuvastatin 40 mg
127 ± 14
127 ± 12
0
Add-on-statin ER-NA/laropiprant
134 ± 12
125 ± 10
−7††,§
DBP (mmHg)
Switch-to-rosuvastatin 40 mg
80 ± 7
79 ± 6
−0.1
Add-on-statin ER-NA/laropiprant
81 ± 9
77 ± 6
−5†,§
TC, mg/dL (mmol/L)
Switch-to-rosuvastatin 40 mg
226 ± 36 (5.8 ± 0.9)
180 ± 30 (4.7 ± 0.8)
−20††
Add-on-statin ER-NA/laropiprant
202 ± 42 (5.2 ± 1.1)
171 ± 37 (4.4 ± 1)
−15††
Triglycerides, mg/dL (mmol/L)
Switch-to-rosuvastatin 40 mg
169 (150–189)
156 (129–183)
−7††
[1.9 (1.7–2.1)]
[1.8 (1.5–2.1)]
Add-on-statin ER-NA/laropiprant
164 (141–187)
123 (97–148)
−25††,§
[1.9 (1.6–2.1)]
[1.4 (1.1–1.7)]
HDL-C, mg/dL (mmol/L)
Switch-to-rosuvastatin 40 mg
55 ± 9 (1.4 ± 0.2)
54 ± 9 (1.4 ± 0.2)
−0.2
Add-on-statin ER-NA/laropiprant
47 ± 11 (1.2 ± 0.3)
53 ± 16 (1.4 ± 0.4)
+13†,§
LDL-C, mg/dL (mmol/L)
Switch-to-rosuvastatin 40 mg
142 ± 45 (3.7 ± 1.2)
98 ± 30 (2.5 ± 0.8)
−30††,‡
Add-on-statin ER-NA/laropiprant
112 ± 35 (2.9 ± 0.9)
91 ± 34 (2.4 ± 0.9)
−19††
Non-HDL-C, mg/dL (mmol/L)
Switch-to-rosuvastatin 40 mg
175 ± 33 (4.5 ± 0.9)
127 ± 26 (3.3 ± 0.7)
−40††
Add-on-statin ER-NA/laropiprant
155 ± 37 (4.0 ± 1)
118 ± 34 (3.1 ± 0.9)
−24††
SBP: systolic blood pressure, DBP: diastolic blood pressure, ER-NA: extended release nicotinic acid, TC: total cholesterol, HDL-C: high-density lipoprotein cholesterol, LDL-C: low-density lipoprotein cholesterol, non-HDL-C: non-high-density lipoprotein cholesterol.
*Values are expressed as mean ± standard deviation (except for triglycerides which are expressed as median (range)). † versus baseline. †† versus baseline. § versus and switch-to-rosuvastatin 40 mg group. ‡ versus the add-on-statin ER-NA/laropiprant group.
